Drug intelligence / Profile preview

lactobacillus acidophilus + bifidobacterium bifidum + lactobacillus reuteri + lactobacillus fermentum

Development stage: Unknown
Lead developer: Kashan University of Medical Sciences
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus acidophilus + bifidobacterium bifidum + lactobacillus reuteri + lactobacillus fermentum is an oral probiotic mixture developed by researchers at Kashan University of Medical Sciences. It is being investigated as a live biotherapeutic product for the treatment of Parkinson's disease (PD). The mixture aims to modulate the gut-brain axis and the immune system. In a randomized, double-blind, placebo-controlled clinical trial involving 60 patients, 12 weeks of supplementation with this 4-strain mixture (8×10^9 CFU) significantly improved motor function as measured by the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Preclinical evidence suggests the mixture reduces lipid peroxidation, prevents neuronal damage in the substantia nigra, and improves cognitive function and rotational behavior in animal models of PD.

Other names: Kashan University probiotic mixture4-strain probiotic mixture

Beyond the preview

Go deeper on lactobacillus acidophilus + bifidobacterium bifidum + lactobacillus reuteri + lactobacillus fermentum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus acidophilus + bifidobacterium bifidum + lactobacillus reuteri + lactobacillus fermentum.

Explore the full profile